Author

Trevor Lissoos 1

1 Eli Lilly and Company,Indianapolis,United States

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler, Andres Yarur, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Sumit Saha, Christina Kifnidi, Dirk Demuth, Haridarshan Patel, Gerassimos J. Mantzaris

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens, Taku Kobayashi, Nathan Morris, Trevor Lissoos, Amy Hoover, Xingyuan Li, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Geert R. D'Haens, Marla C. Dubinsky, Peter Irving, Xingyuan Li, Stefanie Howaldt, Juris Pokrotnieks, Kathryn Krueger, Janelle Laskowski, Trevor Lissoos, Joe Milata

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Isabel Redondo, Brian Feagan, Remo Panaccione, Christian Selinger, Trevor Lissoos, Vipin Arora, Milan Lukas, Katsuyoshi Matsuoka, Toshifumi Hibi

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro, Rish Pai, Taku Kobayashi, Vipul Jairath, Florian Rieder, Isabel Redondo, Trevor Lissoos, Nathan Morris, Mingyang Shan, Laurent Peyrin-Biroulet

Real-world Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results from the EVOLVE study

Andres Yarur, Gerassimos J. Mantzaris, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Christina Kifnidi, Sumit Saha, Dirk Demuth, Haridarshan Patel, Brian Bressler

RISK FACTORS FOR POSTOPERATIVE INFECTION AFTER LOWER GASTROINTESTINAL SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A LARGE EPIDEMIOLOGICAL STUDY

Huifang Liang, Baoguo Jiang, Trevor Lissoos, Sudhakar Manne, Paul Dolin

Risk of reoccurrence of perianal fistulas in patients with Crohn's disease in the United States - A retrospective claims database study

Haridarshan Patel, Dominick Latremouille-Viau, Didier Serre, Trevor Lissoos, Kyle D. Null, Glynn Owen, Sarah Campbell-Hill

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund, Bruce E. Sands, Karen Hamrick Samaan, Xingyuan Li, Nathan Morris, Theresa Hunter Gibble, Isabel Redondo, Trevor Lissoos, Geert R. D'Haens

Item 1 - 10 / 10
1